ReviewInternational journal of nanomedicine2026
Nanomedicine Strategies for Rheumatoid Arthritis: Precision Delivery and Immune Microenvironment Modulation.
Review in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Theranostic Nanoprobes for Rheumatoid Arthritis: From Inflammation Visualization to Guided Precision Therapy.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rheumatoid arthritis (RA) is a chronic autoimmune disorder characterized by synovial inflammation, pannus formation, and progressive joint destruction. Despite their established clinical benefits, conventional antirheumatic drugs remain hampered by poor targeting precision, systemic toxicity, and inadequate immunomodulation of the dysregulated microenvironment. The recent development of nanomedicine technology offers transformative potential to address these therapeutic challenges. This review comprehensively examines the application of advanced nano-platforms in RA management, with particular focus on their dual roles in precision drug delivery and immune microenvironment remodeling. The discussion encompasses multifunctional nanomaterials that enable precise drug transport while actively regulating pathological processes through reactive oxygen species scavenging, hypoxia mitigation, and immune cell reprogramming. Additionally, the integration of diagnostic and therapeutic functions within nanomaterial systems represents a significant advancement in RA theranostics. Finally, translational challenges and future directions are critically analyzed to map the clinical development path for intelligent RA nanomedicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.